Home › Samsung merger to drive growth in biopharmaceutical business
 

Keywords :   


Samsung merger to drive growth in biopharmaceutical business

2015-07-20 13:41:08| Electronics - Topix.net

Boosted by the successful merger of Samsung C&T and Cheil Industries last week, Samsung Group is geared to step up its efforts to expand and develop its biopharmaceutical business, seen by the group as a future growth engine. The $8 billion merger has tightened the group's grip on Samsung BioLogics, the conglomerate's biopharmaceutical business unit.

Tags: business drive growth samsung

Category:Electronics and Electrical

Latest from this category

All news
»
15.11Tropical Storm Sara Graphics
15.11Tropical Storm Sara Forecast Discussion Number 8
15.11Tropical Storm Sara Wind Speed Probabilities Number 8
15.11Tropical Storm Sara Public Advisory Number 8
15.11JBS reports strong Q3 financial results
15.11 20213 105S P7905-P
15.11 ()
15.11Mizuno Energy 25.5
More »